Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: LGG Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Probiotics on Health-related Quality of Life in College Students With Upper Respiratory Infections

NCT01657643
View directory record Official record
Conditions
Upper Respiratory Infection
Interventions
Probiotics, placebo
Dietary Supplement
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 25 Years
Enrollment
231 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Framingham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 20, 2026, 5:32 AM EDT
Completed Phase 4 Interventional Results available

Probiotics to Promote Intestinal Health

NCT02046512
View directory record Official record
Conditions
Communicable Diseases, Infection, Anti-Infective Agents, Therapeutic Uses, Pharmacologic Actions
Interventions
Probiotic, Placebo
Dietary Supplement · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 20, 2026, 5:32 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

NCT04201457
View directory record Official record
Conditions
Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1
Interventions
Dabrafenib, Trametinib, Hydroxychloroquine
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
1 Year to 30 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 20, 2026, 5:32 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

NCT05538130
View directory record Official record
Conditions
Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer, Malignant Neoplasms, Brain Neoplasms, Advanced or Metastatic Solid Tumors, HGG, LGG, Low Grade Glioma, High Grade Glioma, Differentiated Thyroid Cancer, NSCLC (Non-small Cell Lung Cancer)
Interventions
PF-07799544, PF-07799933
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
44
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Rogers, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 20, 2026, 5:32 AM EDT
Terminated Phase 1 Interventional

Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer

NCT01790035
View directory record Official record
Conditions
Gastrointestinal Neoplasms
Interventions
LGG, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 20, 2026, 5:32 AM EDT
Completed Phase 4 Interventional Results available

The Use of Probiotics to Evaluate Colonization With Antimicrobial Resistant Bacteria

NCT01551186
View directory record Official record
Conditions
Infectious Disease of Digestive Tract
Interventions
Lactobacillus rhamnosus GG
Dietary Supplement
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 17, 2018 · Synced Oct 20, 2026, 5:32 AM EDT
Completed Phase 2 Interventional

Probiotic (LGG) for Veterans With PTSD

NCT04150380
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Inflammation
Interventions
Lactobacillus rhamnosus GG (LGG; ATCC strain 53103; CRMTS #11272; PTS #3766), Placebo
Biological · Other
Lead sponsor
VA Eastern Colorado Health Care System
Federal
Eligibility
18 Years to 60 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 20, 2026, 5:32 AM EDT
Recruiting Phase 2 Interventional

LGG Supplementation in Patients With AUD and ALD

NCT05178069
View directory record Official record
Conditions
Alcohol Use Disorder, Alcohol-associated Liver Disease
Interventions
: Placebo for Probiotic, Lactobacillus Rhamnosus GG
Drug · Dietary Supplement
Lead sponsor
University of Louisville
Other
Eligibility
21 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 20, 2026, 5:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Lactobacillus Rhamnosus GG (LGG) on Infant Colic

NCT01279265
View directory record Official record
Conditions
Colic, Inflammation
Interventions
Nutramigen with Enflora, Nutramigen A+
Dietary Supplement
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
3 Weeks to 3 Months
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2015 · Synced Oct 20, 2026, 5:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Fecal Recovery of the Probiotic Bacteria Lactobacillus Rhamnosus GG (LGG) and Bifidobacterium Animalis Subspecies Lactis BB-12 (BB-12) in Healthy Humans Following Daily Consumption of a Probiotic Supplement

NCT01757054
View directory record Official record
Conditions
Fecal Analysis
Interventions
ProNutrients Probiotic
Dietary Supplement
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Oct 20, 2026, 5:32 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis

NCT01773967
View directory record Official record
Conditions
Gastroenteritis
Interventions
LGG, micro-crystalline cellulose
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
3 Months to 48 Months
Enrollment
971 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
10
States / cities
Sacramento, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 20, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

NCT02034110
View directory record Official record
Conditions
Cancer
Interventions
Dabrafenib, Trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
8
States / cities
Little Rock, Arkansas • Santa Monica, California • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 20, 2026, 5:32 AM EDT
Completed Phase 4 Interventional

Rhinovirus Study With Lactobacillus Rhamnosus GG

NCT01229917
View directory record Official record
Conditions
Respiratory Tract Infections [C08.730]
Interventions
Fruit juice with Lactobacillus rhamnosus GG, version 1, Fruit juice with Lactobacillus rhamnosus GG, version 2, Standard fruit juice
Other
Lead sponsor
Valio Ltd
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 7, 2011 · Synced Oct 20, 2026, 5:32 AM EDT
Terminated Phase 1 Interventional Results available

A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

NCT02924038
View directory record Official record
Conditions
Glioma, Malignant Glioma, Astrocytoma, Grade II, Oligodendroglioma, Glioma, Astrocytic, Oligoastrocytoma, Mixed
Interventions
IMA950, poly-ICLC, Varlilumab
Biological
Lead sponsor
Nicholas Butowski
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 20, 2026, 5:32 AM EDT
Recruiting Phase 2 Interventional

Intravesical LGG VS Saline Bladder Wash RCT

NCT05230511
View directory record Official record
Conditions
Spinal Cord Injuries, Neurogenic Bladder
Interventions
Lactobacillus RhamnosusGG, Saline bladder wash
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 20, 2026, 5:32 AM EDT
Not listed Phase 2 Interventional

Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)

NCT02840409
View directory record Official record
Conditions
Low Grade Glioma
Interventions
Vinblastine, Bevacizumab
Drug
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
6 Months to 18 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 20, 2026, 5:32 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

NCT05503797
View directory record Official record
Conditions
Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
Interventions
Plixorafenib
Drug
Lead sponsor
Fore Biotherapeutics
Industry
Eligibility
8 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
30
States / cities
Beverly Hills, California • San Francisco, California • Westwood, Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 20, 2026, 5:32 AM EDT
Recruiting Phase 3 Interventional

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

NCT04166409
View directory record Official record
Conditions
Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma, Metastatic Low Grade Glioma, WHO Grade 1 Glioma, WHO Grade 2 Glioma
Interventions
Biospecimen Collection, Carboplatin, Echocardiography Test, Magnetic Resonance Imaging, Questionnaire Administration, Selumetinib Sulfate, Vincristine Sulfate
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 21 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
124
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 101 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 20, 2026, 5:32 AM EDT
Recruiting Early Phase 1 Interventional

Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG

NCT05555550
View directory record Official record
Conditions
Glioma, Low-grade Glioma, Low Grade Glioma of Brain, Glioma, Malignant, Glioma Intracranial
Interventions
18F-Fluciclovine
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 20, 2026, 5:32 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis

NCT05517928
View directory record Official record
Conditions
Healthy
Interventions
Omeprazole, Lactobacillus rhamnosus GG, Placebo
Drug · Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 20, 2026, 5:32 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Combination Probiotic: BB-12 With LGG (Different Doses) in Treating Children With Autism Spectrum Disorder

NCT03514784
View directory record Official record
Conditions
Autism Spectrum Disorder, Gastrointestinal Symptoms
Interventions
BB-12 with LGG (Higher Dose), Placebo, BB-12 with LGG (Lower Dose)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
4 Years to 16 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 20, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of Lactobacillus Rhamnosus GG Versus Placebo in Elderly Subjects Receiving Live Attenuated Influenza Vaccine

NCT01545349
View directory record Official record
Conditions
Healthy, Influenza
Interventions
Lactobacillus rhamnosus GG ATCC 53103 (LGG), Placebo, Live attenuated influenza vaccine
Biological
Lead sponsor
Patricia L. Hibberd
Other
Eligibility
65 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 20, 2026, 5:32 AM EDT
Completed Not applicable Interventional Results available

Lactobacillus Rhamnosus GG in Reducing Incidence of Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant

NCT02144701
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Lactobacillus rhamnosus GG, laboratory biomarker analysis was not performed because of no differences in the clinical outcomes
Dietary Supplement · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 20, 2026, 5:32 AM EDT
Not yet recruiting Early Phase 1 Interventional

Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTD

NCT07643974
View directory record Official record
Conditions
Spinal Cord Injury, Neurogenic Bladder (NB), Neurogenic Lower Urinary Tract Dysfunction, Multiple Sclerosis, Spina Bifida, Urinary Tract Infection(UTI)
Interventions
Gentamicin, Lactobacillus Rhamnosus GG
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 20, 2026, 5:32 AM EDT